Carl Zeiss Meditec Faces Operational Crisis and Index Demotion

Zeiss Meditec withdraws guidance as Q1 EBITA collapses 75% to €8.1M. Weak US/China markets and a new China tender trigger price pressure. The stock faces MDAX relegation in March 2026.

The medical technology group Carl Zeiss Meditec is confronting a severe operational downturn, marked by plummeting profits, withdrawn guidance, and an imminent demotion from Germany's MDAX index. These developments have pushed the company's share price to levels not seen in a decade.

Financial Performance Collapses

Recent quarterly figures paint a stark picture of the challenges. For the first quarter of fiscal 2025/26, the company's EBITA collapsed to €8.1 million, a staggering decline of over 75% from the €35.2 million reported a year earlier. Revenue fell by 4.8% to €467 million. Consequently, the EBITA margin witnessed a dramatic contraction, dropping from 7.2% to just 1.7%.

Management has attributed this sharp deterioration to a weak sales environment in its core markets of the United States and China, ongoing geopolitical uncertainties, and a broader climate of investment hesitation among customers. A particularly pressing issue is unfolding in China, where a new volume-based procurement tender for intraocular lenses threatens to trigger significant price erosion. This policy shift is increasingly favoring local competitors, who are capturing greater market share.

In response to these headwinds, the company's leadership has completely retracted its full-year targets, which had projected revenue of €2.3 billion and an EBITA margin of 12.5%. A revised forecast, alongside details of a planned restructuring, is not expected before the release of half-year results on May 12, 2026.

Index Demotion Compounds Troubles

The operational crisis has a tangible consequence for the company's stock market standing. Effective March 23, 2026, Carl Zeiss Meditec will be relegated from the MDAX to the smaller SDAX index. This move is more than symbolic; it forces passively managed funds that track the MDAX to divest their holdings. The resulting sell-off increases downward pressure on the share price and adversely affects market liquidity.

The stock's performance clearly reflects the company's predicament. Shares have lost approximately 64% of their value over the past twelve months, trading just above their 52-week low of €23.52. This level stands in stark contrast to the annual high of €69.70 reached in March 2025. Despite the financial strain, the company has announced it will maintain its dividend payment of €0.55 per share, payable on March 31, 2026.

Restructuring Plan Awaited

A potential return to the MDAX index could be considered at the next scheduled review on June 3, 2026. However, this is contingent upon a demonstrable operational recovery that management has yet to deliver. All eyes are now on the upcoming May 12 announcement. The half-year financial report will be scrutinized for the promised concrete restructuring measures, which are expected to focus on product localization and a reprioritization of research and development. This date will be critical for investors assessing whether the proposed strategic realignment holds substantive promise.